SAN DIEGO - Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) presented data today from phase 2 trials of atumelnant, an investigational oral treatment for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, according to a press release statement. The company, valued at $3.63 billion, saw its stock rise 4.7% over the past week following the announcement. According to InvestingPro data, analysts maintain a strong buy consensus with price targets reaching as high as $97.
The company disclosed results from Cohort 4 of its phase 2 CAH trial at the Endocrine Society’s Annual Meeting. In this cohort, eight participants received 80 mg of atumelnant once daily while reducing glucocorticoid doses to target physiologically normal levels.
At week 12, the mean percentage change from baseline in androstenedione morning serum levels was -67%. Seven out of eight participants who completed 12 weeks of treatment achieved a physiologic daily dose of glucocorticoid. Reductions in pre-glucocorticoid serum 11-OHA4 and 11-KT showed mean changes from baseline of -64% and -56% at week 12, respectively.
The company reported no treatment-related severe or serious adverse events to date across all dose levels.
Previously reported data from Cohorts 1-3, where participants maintained their glucocorticoid doses, showed mean androstenedione reductions of -58% at 40 mg, -70% at 80 mg, and -80% at 120 mg.
Crinetics also presented data from a phase 1b/2a ACTH-dependent Cushing’s syndrome trial. In a cohort of six participants receiving 40 mg once daily for 10 days, atumelnant lowered early morning serum cortisol in all participants. Urinary free cortisol remained at or below the upper limit of normal in three of six participants at the end of the dosing period.
Atumelnant is an ACTH receptor antagonist designed to block excess ACTH. The company stated that phase 3 trials in adults and pediatric patients are currently enrolling. An InvestingPro tip notes that analysts anticipate sales growth in the current year as these trials progress. For deeper insights into CRNX’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Crinetics Pharmaceuticals reported its first-quarter 2026 earnings, revealing a significant revenue achievement. The company posted a revenue of $10.7 million, exceeding the forecasted $8.51 million by 25.73%. Additionally, Crinetics announced an earnings per share (EPS) of -$1.23, which was slightly better than the anticipated -$1.28. In another development, Crinetics launched Everyday Advocacy, a patient education program focused on endocrine diseases. This initiative includes digital resources, a mobile app for tracking acromegaly symptoms, and workshops for patients, guided by a steering committee of five patient advocacy organizations. Furthermore, Citizens reiterated its Market Outperform rating for Crinetics Pharmaceuticals, maintaining a price target of $95.00. The firm highlighted the strength of the Palsonify launch. These developments indicate Crinetics’ active engagement in both financial performance and patient support initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for CRNX plus thousands of other stocks and find your next hidden gem with massive upside.